Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
New England Journal of Medicine2020Vol. 382(2), pp. 140–151
Citations Over TimeTop 1% of 2020 papers
Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti, Guillermo Garcia‐Manero, Rena Buckstein, Valeria Santini, María Díez‐Campelo, Carlo Finelli, Mario Cazzola, Osman İlhan, Mikkael A. Sekeres, José Falantes, Beatriz Arrizabalaga, Flavia Salvi, Valentina Giai, Paresh Vyas, David Bowen, Dominik Selleslag, Amy E. DeZern, Joseph G. Jurcic, Ulrich Germing, Katharina S. Götze, Bruno Quesnel, Odile Beyne‐Rauzy, Thomas Cluzeau, Maria-Teresa Voso, Dominiek Mazure, Edo Vellenga, Peter L. Greenberg, Eva Hellström-Lindberg, Amer M. Zeidan, Lionel Adès, Amit Verma, Michael R. Savona, Abderrahmane Laadem, Aziz Benzohra, Jennie Zhang, Anita Rampersad, Diana Dunshee, Peter G. Linde, Matthew L. Sherman, Rami S. Komrokji, Alan F. List
Abstract
Luspatercept reduced the severity of anemia in patients with lower-risk myelodysplastic syndromes with ring sideroblasts who had been receiving regular red-cell transfusions and who had disease that was refractory to or unlikely to respond to erythropoiesis-stimulating agents or who had discontinued such agents owing to an adverse event. (Funded by Celgene and Acceleron Pharma; MEDALIST ClinicalTrials.gov number, NCT02631070; EudraCT number, 2015-003454-41.).
Related Papers
- → Stress Erythropoiesis Model Systems(2017)24 cited
- Influence of erythropoiesis stimulation on 54Mn distribution in rats.(1976)
- → Factors Stimulating Erythropoiesis in Frogs(1963)17 cited
- → Μελέτη της πολυπαραγοντικής αναλγησίας στο μετεγχειρητικό πόνο μετά από λαπαροσκοπική χολοκυστεκτομή(2014)
- → Ιστορική εξέλιξη της έννοιας του placebo από τα μέσα του 19ου αιώνα μέχρι σήμερα(2006)